Bioequivalence issue irks domestic makers

Korean pharmaceutical manufacturers are again concerned about the possible impact of generic drugs’ bioequivalence data fabrication, which has been raised by the National Health Insurance Corporation.

Their reaction came when the NHIC said on June 23 it will file a civil suit against local 92 pharmaceutical manufacturers, calling for the return of medication costs paid to 229 items whose mar...